Aequus Pharmaceuticals Inc V.AQS

Alternate Symbol(s): AQSZF

Healthcare Biotechnology

Aequus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing and commercializing, differentiated products in ophthalmology. Its pipeline products include PAUL Glaucoma Implant, ZIMED PF, and REV-0100 / ReVision. PAUL is a glaucoma drainage device designed to regulate intraocular pressure in the patient’s eyes and prevent further progression of the disease. PAUL has introduced many design features and unified these into one device and offers a solution for patients with moderate to severe glaucoma. ZIMED PF is the first available multi-dose, preservative free, bimatoprost containing product in Canada. REV-0100 is in preclinical development as a treatment for Stargardt disease. REV-0100 works by reducing levels of a toxic lipid called lipid bisretinoid, which accumulates within the retina in material called lipofuscin.

TSXV:AQS - Post by User

Aequus Pharmaceuticals Inc

Bullboard Posts

Post by Stephanovichon Apr 14, 2017 1:57pm

226 Views

Post# 26122813

So we are good... Going up in prediction ! yes !

Aequus Pharmaceuticals (AQS) Analysts See $0.00 EPS

April 13, 2017 - By Richard Conner

Analysts expect Aequus Pharmaceuticals Inc (CVE:AQS) to report $0.00 EPS on May, 5. About 80,770 shares traded. Aequus Pharmaceuticals Inc (CVE:AQS) has risen 6.00% since March 14, 2017 and is uptrending. It has underperformed by 1.26% the S&P500.

Bullboard Posts

@ the Bell: TSX advances to start off Christmas trading week